Spyryx Biosciences
Spyryx Biosciences is a private biopharmaceutical company founded in 2013 and based in Durham, North Carolina, developing next-generation therapeutics for obstructive lung diseases. It operates as a small (11-50 employee), venture-backed clinical-stage biotech financed by 5AM Ventures, Canaan Partners, and Hatteras Venture Partners.
- Company typePrivate
- Founded2013
- HeadquartersDurham, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Spyryx Biosciences firmographics
Firmographics- Name
- Spyryx Biosciences
- Website
- https://spyryxbio.com
- Company type
- Private
- Founded year
- 2013
- Headcount range
- 11–50 employees
- Short description
- Spyryx Biosciences is a private biopharmaceutical company founded in 2013 and based in Durham, North Carolina, developing next-generation therapeutics for obstructive lung diseases. It operates as a small (11-50 employee), venture-backed clinical-stage biotech financed by 5AM Ventures, Canaan Partners, and Hatteras Venture Partners.
- Ownership category
- akta.pro rank
Spyryx Biosciences industry classification
Industry- Product category
- Respiratory Therapeutics
- NAICS
- Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Respiratory & Allergy Pharmaceuticals (HLAIAAAH)
Keywords
Where Spyryx Biosciences is headquartered
LocationHeadquarters
- HQ city
- Durham
- HQ country
- United States
- HQ region
- North America
Markets served
Spyryx Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure
Spyryx Biosciences product offering
Product offeringCore offering
Spyryx Biosciences develops next-generation therapeutics for obstructive lung diseases. The company is a clinical-stage biopharmaceutical firm focused on discovering and advancing novel drug candidates to treat conditions such as chronic obstructive pulmonary disease (COPD), asthma, and related pulmonary disorders. Its work centers on proprietary therapeutic approaches targeting the underlying biology of obstructive airway disease.
Differentiator
Problem solved
Functional benefit
Products and services
- Next-generation therapeutics for obstructive lung diseases Proprietary therapeutic drug candidates in development for the treatment of obstructive lung diseases, including chronic obstructive pulmonary disease (COPD), asthma, and related pulmonary disorders. The pipeline is intended for eventual out-licensing, partnership, or commercialization with pharmaceutical companies serving patients with obstructive airway conditions.
Companies that use Spyryx Biosciences
Customer profileIdeal customer profiles1 record
Spyryx Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Spyryx Biosciences competitors and assessment
Company assessmentBroad incumbents
- Novartis: Major pharmaceutical company with respiratory franchise (Xolair via partnership with Genentech, Ultibro, Enerzair). Broad incumbent reflecting the universe of large acquirers/licensors active in obstructive lung disease.
- GSK: One of the largest pharmaceutical companies in respiratory medicine (Advair, Trelegy Ellipta, Nucala). Broad incumbent comparison because any successful next-generation obstructive lung therapy would directly compete with GSK's established inhaled franchise, and GSK is a likely strategic acquirer.
- AstraZeneca: Major respiratory pharma with a deep COPD/asthma franchise (Symbicort, Breztri, Fasenra, Tezspire). Broad incumbent peer — sets the standard of care against which any "next-generation" obstructive lung therapeutic must compete, and is a plausible licensing/acquisition counterparty.
- Boehringer Ingelheim: Long-standing respiratory player (Spiriva, Ofev, Atrovent) with deep investment in COPD biologics and inhaled medicines. Broad incumbent peer and likely strategic acquirer for differentiated respiratory programs of the type Spyryx is developing.
Direct peers
- Trevena: Small clinical-stage biopharma with a pipeline spanning respiratory indications including acute lung injury and other pulmonary conditions. Comparable as a similarly sized specialty biotech pursuing niche respiratory opportunities.
- Verona Pharma: Late-stage clinical biotech developing inhaled therapeutics for chronic obstructive lung diseases (COPD). Direct peer because it operates in the same narrow therapeutic area (obstructive lung disease) with similar inhaled/small-molecule modality — though at a more advanced clinical stage.
- Inhalon Biopharma: Early-stage biotech focused on inhaled therapeutics for respiratory infections and pulmonary conditions. Comparable as a peer-stage, inhaled-modality respiratory developer and as a potential M&A candidate or co-developer.
- Pulmatrix: Small clinical-stage biotech developing inhaled therapeutics for respiratory diseases including COPD and other obstructive lung conditions. Direct comparison due to similar stage, inhaled modality, and obstructive lung disease focus.
- Theravance Biopharma: Specialty biopharma developing respiratory therapeutics including inhaled COPD/asthma treatments (e.g., Yupelri). Direct peer in terms of indication, modality, and competitor set, though considerably larger and with marketed assets.
Emerging players
- Arcturus Therapeutics: Clinical-stage biotech working on inhaled mRNA therapeutics for respiratory diseases including cystic fibrosis (an obstructive lung condition). Emerging peer due to overlapping respiratory therapeutic area and inhaled delivery platform approach.
Market position
Customer concentration
Spyryx Biosciences social profiles
Digital presenceSpyryx Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Spyryx Biosciences leadership team
Management profileNumber of profiles
Profiles1 record
Spyryx Biosciences funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Spyryx Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Spyryx Biosciences
What does Spyryx Biosciences do?
Spyryx Biosciences develops next-generation therapeutics for obstructive lung diseases. The company is a clinical-stage biopharmaceutical firm focused on discovering and advancing novel drug candidates to treat conditions such as chronic obstructive pulmonary disease (COPD), asthma, and related pulmonary disorders. Its work centers on proprietary therapeutic approaches targeting the underlying biology of obstructive airway disease.
When was Spyryx Biosciences founded?
Spyryx Biosciences was founded in 2013. It employs 11 to 50 people.
Where is Spyryx Biosciences based?
Spyryx Biosciences is headquartered in Durham, United States, in the North America region.
Who are Spyryx Biosciences's main competitors?
Broad incumbents on record are Novartis, GSK, AstraZeneca and Boehringer Ingelheim. Direct peers are Trevena, Verona Pharma, Inhalon Biopharma, Pulmatrix and Theravance Biopharma. Arcturus Therapeutics is listed as an emerging player.
Does Spyryx Biosciences have an API?
No public API is recorded for Spyryx Biosciences.
What industry is Spyryx Biosciences in?
Spyryx Biosciences's product category is Respiratory Therapeutics. Its primary akta.pro industry code is HLAIAAAH, Respiratory & Allergy Pharmaceuticals. Its NAICS code is 5417 and its SIC code is 2834.